ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical ...

CytomX Therapeutics Inc . (NASDAQ:CTMX) stock has reached a new 52-week low, trading at $0.76, as the biopharmaceutical company faces a challenging market environment. Despite the recent decline, ...

NIH’s plan to cut what it pays universities and other entities for indirect costs associated with scientific research would create “extremely challenging” short- and long-term impacts, according to a ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Here’s a look at what the Trump administration’s decision to cut overhead funding for biomedical research means for ...

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at ...

Cybin pushes forward with Phase 3 depression trials after posting a narrower loss, while securing a $100M funding program.

What's at stake in cancer research as the Trump administration moves to cut "indirect funding" to universities? The immediate past leader of the National Cancer Institute says clinical trials will be ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

Observational studies are critical tools in clinical research and public health response, but challenges arise in ensuring ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...